Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer

SHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therap...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2022-12, Vol.28 (24), p.5238-5240
Hauptverfasser:	Miller, Kathryn M, Friedman, Claire F
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Bispecific - therapeutic use B7-H1 Antigen - immunology Female Humans Immunotherapy Neoplasm Recurrence, Local Transforming Growth Factor beta Uterine Cervical Neoplasms - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	SHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therapeutic approach to do so. See related article by Feng et al., p. 5297.
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-22-1779